Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.

Yeh P, Chen H, Andrews J, Naser R, Pao W, Horn L.

Clin Cancer Res. 2013 Apr 1;19(7):1894-901. doi: 10.1158/1078-0432.CCR-12-1894. Epub 2013 Jan 23.

2.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Murphy M, Stordal B.

Drug Resist Updat. 2011 Jun;14(3):177-90. doi: 10.1016/j.drup.2011.02.004. Epub 2011 Mar 24. Review.

PMID:
21435938
3.

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.

Westwood M, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, Misso K, Severens J, Kleijnen J.

Health Technol Assess. 2014 May;18(32):1-166. doi: 10.3310/hta18320. Review.

4.

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.

Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE.

Clin Cancer Res. 2015 Dec 15;21(24):5439-44. doi: 10.1158/1078-0432.CCR-15-0354. Review.

6.

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Ohashi K, Maruvka YE, Michor F, Pao W.

J Clin Oncol. 2013 Mar 10;31(8):1070-80. doi: 10.1200/JCO.2012.43.3912. Epub 2013 Feb 11. Review.

7.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F.

Clin Lung Cancer. 2014 May;15(3):173-81. doi: 10.1016/j.cllc.2013.12.002. Epub 2013 Dec 27. Review.

PMID:
24486058
8.

Emerging treatment for advanced lung cancer with EGFR mutation.

Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H.

Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Review.

PMID:
26153235
9.

AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.

Remon J, Planchard D.

Future Oncol. 2015 Nov;11(22):3069-81. doi: 10.2217/fon.15.250. Epub 2015 Oct 9. Review.

PMID:
26450446
10.

Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.

Piotrowska Z, Sequist LV.

Cancer J. 2015 Sep-Oct;21(5):371-7. doi: 10.1097/PPO.0000000000000147. Review.

PMID:
26389761
11.

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

Yasuda H, Kobayashi S, Costa DB.

Lancet Oncol. 2012 Jan;13(1):e23-31. doi: 10.1016/S1470-2045(11)70129-2. Epub 2011 Jul 19. Review. Erratum in: Lancet Oncol. 2011 Dec;12(13):1182.

PMID:
21764376
12.

Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer.

Galvani E, Alfieri R, Giovannetti E, Cavazzoni A, La Monica S, Galetti M, Fumarola C, Bonelli M, Mor M, Tiseo M, Peters GJ, Petronini PG, Ardizzoni A.

Curr Pharm Des. 2013;19(5):818-32. Review.

PMID:
22973953
13.

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].

Brosseau S, Viala M, Varga A, Planchard D, Besse B, Soria JC.

Bull Cancer. 2015 Sep;102(9):749-57. doi: 10.1016/j.bulcan.2015.05.001. Epub 2015 Jul 30. Review. French.

PMID:
26235419
14.

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S.

Lancet Oncol. 2008 Oct;9(10):962-72. doi: 10.1016/S1470-2045(08)70206-7. Epub 2008 Sep 17. Review.

PMID:
18804418
16.

Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.

Wijesinghe P, Bollig-Fischer A.

Adv Exp Med Biol. 2016;890:1-23. doi: 10.1007/978-3-319-24932-2_1. Review.

PMID:
26703796
17.

The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer.

Xie J, Zhang X.

J Genet Genomics. 2016 Jan 20;43(1):3-10. doi: 10.1016/j.jgg.2015.09.003. Epub 2015 Sep 15. Review.

18.

Acquired resistance to targeted therapies in advanced non-small cell lung cancer: new strategies and new agents.

West H, Oxnard GR, Doebele RC.

Am Soc Clin Oncol Educ Book. 2013. doi: 10.1200/EdBook_AM.2013.33.e272. Review.

19.

Beyond histology: translating tumor genotypes into clinically effective targeted therapies.

Meador CB, Micheel CM, Levy MA, Lovly CM, Horn L, Warner JL, Johnson DB, Zhao Z, Anderson IA, Sosman JA, Vnencak-Jones CL, Dahlman KB, Pao W.

Clin Cancer Res. 2014 May 1;20(9):2264-75. doi: 10.1158/1078-0432.CCR-13-1591. Epub 2014 Mar 5. Review.

20.

Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.

Carter CA, Zeman K, Day RM, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B.

Oncotarget. 2016 Jun 28;7(26):40781-40791. doi: 10.18632/oncotarget.8205. Review.

Supplemental Content

Support Center